The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of Salivary Cortisol Hypertension Assay

18 Dec 2015 09:43

RNS Number : 5543J
Immunodiagnostic Systems Hldgs PLC
18 December 2015
 

Launch of IDS-iSYS Salivary Cortisol Hypertension Assay

18 December 2015

 

Immunodiagnostic Systems Holdings plc.

Launch of IDS-iSYS Salivary Cortisol Hypertension Assay

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, has launched the IDS-iSYS Salivary Cortisol assay in the European market - a fully automated assay for use with the IDS-iSYS Automated System.

The launch of the IDS-iSYS Salivary Cortisol assay enhances the IDS Hypertension panel, which also includes the automated IDS-iSYS Aldosterone and IDS-iSYS Direct Renin immunoassays.

The IDS-iSYS Salivary Cortisol assay measures a patient's salivary cortisol and offers clinicians an easy, non-invasive way to diagnose diseases of cortisol imbalance such as Cushing's Syndrome (CS). One sign of CS is a higher than expected level of cortisol, which can often lead to hypertension.

As the fastest salivary cortisol automated test on the market the IDS-iSYS Salivary Cortisol assay allows laboratories to benefit from a reduced time to first result.

The global market size of salivary cortisol testing is estimated to be around £5 - £10 million.

For further information:

Immunodiagnostic Systems Holdings plc Telephone: +44(0)191 519 0660Patricio Lacalle, CEOJaap Stuut, Marketing DirectorPeel Hunt LLP Telephone: +44(0)207 418 8900James Steel

 

About Immunodiagnostic Systems Holdings plc.:A Specialist in Endocrinology TestingImmunodiagnostic Systems Holdings plc (IDS) is a leading in vitro diagnostic solution provider to the clinical laboratory market. IDS develop, manufacture and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients. The IDS immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields.

IDS was founded in 1977 and trades on the Alternative Investment Market (AIM; trading symbol IDH) of the London Stock Exchange.IDS is a global company headquartered in the UK with around 400 employees worldwide. The group's products are developed and manufactured at their facilities in Europe. IDS serve customers through regional offices in Europe, U.S.A. and Brazil. The group's network of distributors work on IDS' behalf to serve customers throughout the rest of the world.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGCBDDDSBBGUI
Date   Source Headline
27th Oct 20174:23 pmRNSTransaction in Own Shares
23rd Oct 20175:38 pmRNSTransaction in Own Shares
20th Oct 20174:30 pmRNSH1 Trading Update
5th Oct 20179:49 amRNSHolding(s) in Company
5th Oct 20179:42 amRNSHolding(s) in Company
5th Oct 20179:39 amRNSHolding(s) in Company
2nd Oct 20176:08 pmRNSHolding(s) in Company
22nd Sep 20177:25 amRNSTransaction in Own Shares
20th Sep 20176:09 pmRNSTransaction in Own Shares
18th Sep 20173:23 pmRNSTransaction in Own Shares
10th Aug 20172:00 pmRNSLaunch of IDS-iSYS
10th Aug 20178:37 amRNSTransaction in Own Shares
9th Aug 20177:00 amRNSTransaction in Own Shares
2nd Aug 20179:30 amRNSDirector/PDMR Shareholding
2nd Aug 20178:33 amRNSHolding(s) in Company
2nd Aug 20178:30 amRNSHolding(s) in Company
27th Jul 20173:45 pmRNSResult of AGM
27th Jul 20178:00 amRNSTransaction in Own Shares
27th Jul 20177:00 amRNSAGM Statement
24th Jul 20177:00 amRNSTransaction in Own Shares
3rd Jul 20174:12 pmRNSDirector/PDMR Shareholding
28th Jun 20178:28 amRNSDirector/PDMR Shareholding
22nd Jun 20175:33 pmRNSDirector/PDMR Shareholding
21st Jun 20177:30 amRNSPublication of Annual Report and Accounts
21st Jun 20177:01 amRNSShare Buyback Programme
21st Jun 20177:00 amRNSFinal Results
21st Apr 20177:00 amRNSTrading Update
23rd Mar 20179:14 amRNSDirector/PDMR Shareholding
13th Mar 20178:31 amRNSDirectorate Change
1st Mar 201710:01 amRNSLaunch of IDS-iSYS InaKtif MGP assay
24th Feb 20173:31 pmRNSUpdate on CEO Appointment
7th Feb 20172:46 pmRNSHolding(s) in Company
2nd Feb 20173:14 pmRNSLaunch of IDS-iSYS ACTH assay
26th Jan 20173:05 pmRNSHolding(s) in Company
20th Jan 20174:24 pmRNSDirector Dealing
20th Jan 201710:30 amRNSHolding(s) in Company
19th Jan 20171:12 pmRNSDirectorate Change
18th Jan 201712:26 pmRNSHolding(s) in Company
11th Jan 20173:14 pmRNSDirector/PDMR Shareholding
5th Jan 20175:35 pmRNSHolding(s) in Company
5th Jan 20174:38 pmRNSHolding(s) in Company
25th Nov 20168:00 amRNSHalf-year Report
21st Oct 20167:00 amRNSH1 Trading Update
19th Oct 20167:00 amRNSLaunch of IDS-iSYS Total Testosterone assay
28th Jul 20163:18 pmRNSResult of AGM
28th Jul 20167:00 amRNSAGM Statement
11th Jul 201611:46 amRNSDirector/PDMR Shareholding
5th Jul 201610:07 amRNSDirector/PDMR Shareholding
30th Jun 20166:15 pmRNSDirector/PDMR Shareholding
28th Jun 20166:13 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.